AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31553469
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy plus CBT
Trial: 31553469
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy plus CBT
Trial: 25261425
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (electrical stimulation and low-level laser therapy)
Trial: 25261425
Drug: Laser group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser group (low-level laser therapy dose of 4-6 J per point, six points at the knee joint)
Trial: 24195208
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment with disperse-dense wave applied at specific acupuncture points (Taiyang, Xiaguan, Heliao)
Trial: 22053565
Drug: Intravitreal Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Bevacizumab (IVB) 1.25 mg/0.05 ml
Trial: 22053565
Drug: Intravitreal Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT) 1.25 mg/0.05 ml and 2 mg/0.05 ml
Trial: 19447807
Drug: Optimized anti-arrhythmic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized anti-arrhythmic drug (AAD) therapy
Trial: 9443527
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dose of diazepam
Trial: 8504712
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen patches (0.05 mg daily estradiol) with medroxyprogesterone acetate (5 mg orally for 14 days per month)
Trial: 8504712
Drug: Calcium group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium group (500 mg calcium daily)
Trial: 8504712
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen vs. calcium
Trial: 3673928
Drug: 65 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg/d AA intake for 2 weeks
Trial: 3673928
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d AA intake for 4 weeks
Trial: 3673928
Drug: 605 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 605 mg/d AA intake for 3 weeks
Trial: 3673928
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d AA intake for 4 days
Trial: 3673928
Drug: 605 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 605 mg/d AA intake for 4 days
Trial: 3673928
Drug: 65 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg/d AA intake for 3 days
Trial: 3673928
Drug: AA intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA intake calculated to maintain plasma AA levels of at least 0.4 mg/dL (23 mumol/L)
Trial: 29300728
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment (IIT)
Trial: 23828313
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal anesthetic (TNA)
Trial: 20224514
Drug: Fixed-dose mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed-dose mycophenolate mofetil (MMF)
Trial: 18641546
Drug: Tacrolimus treatment
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus treatment
Trial: 1850946
Drug: Oral diazepam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam, 5 mg
Trial: 1850946
Drug: Oral diazepam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam, 10 mg
Trial: 1850946
Drug: Oral midazolam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral midazolam, 15 mg
Trial: 6786536
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of folic acid a day before and during early pregnancy
Trial: 31415123
Drug: Long-term low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Long-term low-dose clarithromycin (CAM) therapy
Trial: 31415123
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no clarithromycin therapy)
Trial: 26073493
Drug: Lanreotide (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide (90 mg every 4 weeks) for 6 months
Trial: 23147275
Drug: Beating Heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beating Heart Problems programme (8-week group programme based on cognitive behaviour therapy and motivational interviewing)
Trial: 22703478
Drug: Carvedilol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (12.5 mg)
Trial: 11757472
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg)
Trial: 17336229
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg intravenously three times daily for 5 days)
Trial: 17336229
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline administered in equal volume)
Trial: 15111377
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (4 mg/patch) twice weekly for 6 months
Trial: 2184564
Drug: Cisplatin alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin alone, modified MVAC scheme, or combination of cisplatin and methotrexate (3 cycles)
Trial: 22216504
Drug: Frusemide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (120 mg daily)
Trial: 30658699
Drug: Treatment escalation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment escalation (initial prednisone and methotrexate, changed every 4 months)
Trial: 30658699
Drug: Treatment tapering
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment tapering (tapering MTX)
Trial: 30658699
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no DFR)
Trial: 30658699
Drug: Drug-free remission
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-free remission (DFR)
Trial: 28298021
Drug: Parenteral nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral nimodipine (1-2 mg/hour) and hydroxyethyl starch (HES) from the day before surgery until the 7th postoperative day
Trial: 28298021
Drug: Parenteral nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral nimodipine and HES
Trial: 1108694
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prophylactic treatment)
Trial: 23343649
Drug: Continuous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous tranexamic acid (TA) dosing: 10 mg/kg followed by an infusion of 1 mg·kg·h(‐1) throughout the operation, and 10 mg/kg into the CPB.
Trial: 23343649
Drug: Discontinuous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinuous tranexamic acid (TA) dosing: 10 mg/kg, then 10 mg/kg into the CPB and 10 mg·kg·h(‐1) at the end of CPB.
Trial: 28262529
Drug: Intravenous neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous neostigmine 2.5mg
Trial: 28262529
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide 20mg
Trial: 28262529
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of neostigmine and metoclopramide
Trial: 18688808
Drug: Naltrexone (opiate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (opiate blocker) administered in a double-blind, crossover design for 7 weeks with an additional 14 hr/week of observation
Trial: 12551734
Drug: Lavandula tincture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavandula tincture (1:5 in 50% alcohol) 60 drops/day plus placebo tablet (Group A)
Trial: 12551734
Drug: Imipramine 100
RxNorm normalized name: trimipramine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 100 mg/day plus placebo drop (Group B)
Trial: 12551734
Drug: Imipramine 100
RxNorm normalized name: trimipramine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 100 mg/day plus lavandula tincture 60 drops/day (Group C)
Trial: 10546926
Drug: filgrastim (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: filgrastim (all doses)
Trial: 6838746
Drug: Intraoperative methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative methadone 10 mg i.v. at induction of anaesthesia
Trial: 6838746
Drug: Postoperative methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative methadone 10 mg i.v. following operation
Trial: 27734219
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg plus caffeine 65 mg (test)
Trial: 27734219
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg (reference)
Trial: 22505700
Drug: Double filtration
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double filtration plasmapheresis (DFPP) in combination with leflunomide and methotrexate (MTX)
Trial: 18041488
Drug: Doxepin 3
RxNorm normalized name: doxepin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 3 mg
Trial: 18041488
Drug: Doxepin 1
RxNorm normalized name: doxepin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 1 mg
Trial: 21102997
Drug: Doxepin 1
RxNorm normalized name: doxepin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 1 mg and 3 mg
Trial: 12641399
Drug: SP monotherapy
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP monotherapy
Trial: 12641399
Drug: SP/CQ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP/CQ combination therapy
Trial: 12641399
Drug: SP/AQ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP/AQ combination therapy
Trial: 10462143
Drug: Cilnidipine (CNP)
RxNorm normalized name: cilnidipine
DrugBank: Cilnidipine (DB09232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine (CNP) 10 mg/day
Trial: 7607610
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone administration
Trial: 2088249
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (500 mg orally, 8 hourly)
Trial: 2088249
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo tablet thrice daily)
Trial: 41544
Drug: Temazepam 30
RxNorm normalized name: temazepam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 30 mg at night
Trial: 31751687
Drug: Inonotus obliquus
RxNorm normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inonotus obliquus polysaccharides (IOP) at a dosage of 50 mg/kg
Trial: 31751687
Drug: Compound C
RxNorm normalized name: Compound cooking fat
DrugBank: Dorsomorphin (DB08597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound C (chemical inhibitor of AMPK)
Trial: 31374046
Drug: Escitalopram (or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (or another antidepressant) for 4 weeks after initial treatment
Trial: 22520627
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil solution
Trial: 9786311
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion of 5-FU
Trial: 16505413
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI)
Trial: 9786311
Drug: Intravenous fluoropyrimidine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluoropyrimidine-based therapies
Trial: 8723583
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (300 IU/kg daily) for 14 or 9 days perioperatively, commencing 10 and 5 days preoperatively, respectively.
Trial: 2182401
Drug: Cimetropium bromide
RxNorm normalized name: cimetropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetropium bromide (50 mg tid)
Trial: 31086540
Drug: NIPPV in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPPV in addition to medicines and oxygen therapy (Intervention Group-A)
Trial: 31086540
Drug: Multidisciplinary comprehensive
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary comprehensive respiratory rehabilitation in addition to NIPPV and medicines and oxygen therapy (Intervention Group-B)
Trial: 31086540
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medicines and oxygen therapy)
Trial: 23265346
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg/day
Trial: 23265346
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg/day (on-treatment analysis)
Trial: 23265346
Drug: No colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No colchicine (on-treatment analysis)
Trial: 21358204
Drug: XELOX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX (oxaliplatin + oral capecitabine)
Trial: 14585280
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PB and demethylating agents
Trial: 14585280
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of a demethylating agent and HDAC inhibitors
Trial: 10670599
Drug: Standard nomogram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nomogram for managing anticoagulation therapy (Group A, n = 10)
Trial: 10670599
Drug: No nomogram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nomogram for managing anticoagulation therapy (Group B, n = 10)
Trial: 2200995
Drug: Cefuroxime-axetil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime-axetil (250 mg bid)
Trial: 2200995
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (500 mg/125 mg bid)
Trial: 31150573
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (gemcitabine 1 g/m² on days 1 and 8, cisplatin 80 mg/m² on day 1, every 3 weeks for three cycles) plus concurrent chemoradiotherapy
Trial: 31150573
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (gemcitabine and cisplatin) plus concurrent chemoradiotherapy
Trial: 31150573
Drug: Standard-therapy (chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-therapy (chemoradiotherapy alone)
Trial: 26513512
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy and Exposure therapy
Trial: 17990450
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Chinese herbal medicine (Kangliu Zengxiao Decoction during chemotherapy and Feiyanning Decoction after chemotherapy)
Trial: 17990450
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Chinese herbal medicine
Trial: 7919085
Drug: 24-hour sodium
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-hour sodium excretion rates
Trial: 7919085
Drug: 24-hour magnesium/creatinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour magnesium/creatinine excretion ratio
Trial: 7919085
Drug: 24-hour sodium
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-hour sodium excretion rate
Trial: 7919085
Drug: 24-hour taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24-hour taurine excretion rate
Trial: 29705158
Drug: Functional electrostimulation
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional electrostimulation + standard medical treatment
Trial: 29705158
Drug: Calisthenic exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calisthenic exercises + standard medical treatment
Trial: 18812677
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (control group)
Trial: 11192143
Drug: Citalopram oral
RxNorm normalized name: citalopram Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram oral solution (10 mg/5 mL), 60 mg dose
Trial: 11192143
Drug: Citalopram tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram tablet, 60 mg dose
Trial: 2418295
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous amrinone (200-400-800 micrograms/kg/h)
Trial: 2418295
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous amrinone (800-1600-3200 micrograms/kg/h)
Trial: 22298163
Drug: One venous
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One venous line cannulation with heparin
Trial: 22298163
Drug: Separate cannulation
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate cannulation without heparin
Trial: 15761020
Drug: G-CSF during
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF during chemotherapy (Group B)
Trial: 15761020
Drug: G-CSF after
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF after chemotherapy until day 28 or recovery (Group C)
Trial: 15761020
Drug: G-CSF during
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF during and after chemotherapy (Group D)
Trial: 15761020
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF (Group A)
Trial: 15761020
Drug: G-CSF during
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF during chemotherapy (Groups B + D)
Trial: 15761020
Drug: G-CSF after
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF after chemotherapy (Groups C + D)
Trial: 15761020
Drug: G-CSF after
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF after chemotherapy
Trial: 9797551
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution alone (Control)
Trial: 2468933
Drug: Flecainide 100
RxNorm normalized name: flecainide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 100 mg b.i.d.
Trial: 2468933
Drug: Quinidine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine 500 mg b.i.d.
Trial: 2468933
Drug: Flecainide 100
RxNorm normalized name: flecainide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 100 mg b.i.d. (after dose adjustment)
Trial: 2468933
Drug: Quinidine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine 500 mg b.i.d. (before and after dose adjustment)
Trial: 23294276
Drug: Tofacitinib 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 15 mg twice daily
Trial: 28124822
Drug: Liraglutide/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide/metformin
Trial: 11703422
Drug: Placebo/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/metformin